ID

24697

Description

Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS); ODM derived from: https://clinicaltrials.gov/show/NCT00480987

Link

https://clinicaltrials.gov/show/NCT00480987

Keywords

Versions (1)
  1. 8/13/17 8/13/17 -
Uploaded on

August 13, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Myelodysplastic Syndromes NCT00480987

English

Eligibility Myelodysplastic Syndromes NCT00480987

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed relapsed or refractory acute myeloid leukemia (aml) or high-risk myelodysplastic syndrome.
Description

Recurrent adult acute myeloid leukemia | Acute Myelocytic Leukemia refractory | Myelodysplastic syndrome High risk

Data type

boolean

Alias
UMLS CUI [1]
C0278780
UMLS CUI [2,1]
C0023467
UMLS CUI [2,2]
C0205269
UMLS CUI [3,1]
C3463824
UMLS CUI [3,2]
C0332167
performance status 0-2 (zubrod scale).
Description

Zubrod Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C3714786
serum creatinine equal or less than 1.3 mg/dl or creatinine clearance > 40 ml/min.
Description

Creatinine measurement, serum | Creatinine clearance measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0373595
bilirubin </= 2 mg/dl; serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) </= 3 times the upper limit of normal (uln) for the reference lab unless due to leukemia or congenital hemolytic disorder (for bilirubin).
Description

Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1278039
written informed consent.
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
no untreated or uncontrolled life-threatening infection.
Description

Life-threatening infection untreated | Life-threatening infection Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C1859430
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C1859430
UMLS CUI [2,2]
C0205318
no oxaliplatin, fludarabine, or cytarabine intolerance.
Description

Intolerance to oxaliplatin | Intolerance to fludarabine | Intolerance to Cytarabine

Data type

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0069717
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C0059985
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C0010711
no pregnancy or lactation. female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraception.
Description

Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods | Postmenopausal state Duration Contraceptive methods | Gender Contraceptive methods

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3,1]
C3831118
UMLS CUI [3,2]
C0700589
UMLS CUI [4,1]
C0232970
UMLS CUI [4,2]
C0449238
UMLS CUI [4,3]
C0700589
UMLS CUI [5,1]
C0079399
UMLS CUI [5,2]
C0700589
no chemotherapy or radiation therapy within 4 weeks of study entry. hydroxyurea is allowed prior to starting therapy in the setting of rapidly proliferating disease.
Description

Chemotherapy | Therapeutic radiology procedure | Hydroxyurea pre treatment allowed | Disease Proliferating Rapidly

Data type

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1522449
UMLS CUI [3,1]
C0020402
UMLS CUI [3,2]
C2709094
UMLS CUI [3,3]
C0683607
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C1514485
UMLS CUI [4,3]
C0456962
no other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent or cooperate and participate in the study or to interfere with the interpretation of the results.
Description

Medical condition Interferes with Informed Consent | Medical condition Interferes with Compliance behavior | Medical condition Interferes with Study Subject Participation Status | Medical condition Interferes with Interpretation Research results | Mental disorder | Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0021430
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C1321605
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C2348568
UMLS CUI [4,1]
C3843040
UMLS CUI [4,2]
C0521102
UMLS CUI [4,3]
C0459471
UMLS CUI [4,4]
C0683954
UMLS CUI [5]
C0004936
UMLS CUI [6]
C0038586
Back to the top of the page

Similar models

Eligibility Myelodysplastic Syndromes NCT00480987

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Recurrent adult acute myeloid leukemia | Acute Myelocytic Leukemia refractory | Myelodysplastic syndrome High risk
Item
histologically or cytologically confirmed relapsed or refractory acute myeloid leukemia (aml) or high-risk myelodysplastic syndrome.
boolean
C0278780 (UMLS CUI [1])
C0023467 (UMLS CUI [2,1])
C0205269 (UMLS CUI [2,2])
C3463824 (UMLS CUI [3,1])
C0332167 (UMLS CUI [3,2])
Zubrod Performance Status
Item
performance status 0-2 (zubrod scale).
boolean
C3714786 (UMLS CUI [1])
Creatinine measurement, serum | Creatinine clearance measurement
Item
serum creatinine equal or less than 1.3 mg/dl or creatinine clearance > 40 ml/min.
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Serum total bilirubin measurement
Item
bilirubin </= 2 mg/dl; serum glutamic oxaloacetic transaminase (sgot) or serum glutamic pyruvic transaminase (sgpt) </= 3 times the upper limit of normal (uln) for the reference lab unless due to leukemia or congenital hemolytic disorder (for bilirubin).
boolean
C1278039 (UMLS CUI [1])
Informed Consent
Item
written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Life-threatening infection untreated | Life-threatening infection Uncontrolled
Item
no untreated or uncontrolled life-threatening infection.
boolean
C1859430 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C1859430 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Intolerance to oxaliplatin | Intolerance to fludarabine | Intolerance to Cytarabine
Item
no oxaliplatin, fludarabine, or cytarabine intolerance.
boolean
C1744706 (UMLS CUI [1,1])
C0069717 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C0059985 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0010711 (UMLS CUI [3,2])
Pregnancy | Breast Feeding | Childbearing Potential Contraceptive methods | Postmenopausal state Duration Contraceptive methods | Gender Contraceptive methods
Item
no pregnancy or lactation. female patients of childbearing potential (including those < 1 year post-menopausal) and male patients must agree to use contraception.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
C0232970 (UMLS CUI [4,1])
C0449238 (UMLS CUI [4,2])
C0700589 (UMLS CUI [4,3])
C0079399 (UMLS CUI [5,1])
C0700589 (UMLS CUI [5,2])
Chemotherapy | Therapeutic radiology procedure | Hydroxyurea pre treatment allowed | Disease Proliferating Rapidly
Item
no chemotherapy or radiation therapy within 4 weeks of study entry. hydroxyurea is allowed prior to starting therapy in the setting of rapidly proliferating disease.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C0020402 (UMLS CUI [3,1])
C2709094 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])
C0012634 (UMLS CUI [4,1])
C1514485 (UMLS CUI [4,2])
C0456962 (UMLS CUI [4,3])
Medical condition Interferes with Informed Consent | Medical condition Interferes with Compliance behavior | Medical condition Interferes with Study Subject Participation Status | Medical condition Interferes with Interpretation Research results | Mental disorder | Substance Use Disorders
Item
no other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent or cooperate and participate in the study or to interfere with the interpretation of the results.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1321605 (UMLS CUI [2,3])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C2348568 (UMLS CUI [3,3])
C3843040 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0459471 (UMLS CUI [4,3])
C0683954 (UMLS CUI [4,4])
C0004936 (UMLS CUI [5])
C0038586 (UMLS CUI [6])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial